GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Organon Gets More Skin in the Game by Acquiring Roivant's Dermatology Subsidiary
Organon plans to acquire Dermavant for up to $1.2 billion, gaining its commercialized plaque psoriasis drug Vtama, which is under FDA review for atopic dermatitis. Vtama sales grew to $75.1 million in FY2023, but face competition in a crowded market. Organon aims to leverage its global scale to expand Vtama's reach.
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
Douglas B. Snyder joins IDEAYA Biosciences as SVP, General Counsel, bringing over 25 years of legal experience from GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDA.
Approval Sought for Belantamab Mafodotin Combos for R/R Multiple Myeloma in Japan
Japan’s Ministry of Health, Labour, and Welfare accepted an NDA for belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone or pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, supported by phase 3 DREAMM-7 and DREAMM-8 studies showing progression-free survival benefits. A trend toward overall survival was observed, though not statistically significant. A Japan expansion cohort will further examine these protocols.
Related Clinical Trials:
Bridging Gaps in Clinical Trials
Life-science firms are enhancing clinical trial diversity through partnerships, such as GSK's new leadership role and Trial Equity's collaboration with Miller Tanner Associates, which promotes eLearning and diversity workshops to address infrastructure gaps in recruiting diverse patient populations.
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
FDA approves AstraZeneca's Fasenra for EGPA, based on MANDARA trial data showing 60% remission and 41% OCS tapering, comparable to GSK's Nucala.
Ins & Outs: C-suite rejigs at Regenxbio, Kyverna and Mirador
Kyverna appoints Warner Biddle as CEO, Christi Shaw to board. Regenxbio welcomes Mitchell Chan as CFO. Mirador Therapeutics appoints Gregg Gilbert as CFO.
Novartis' Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
Novartis' Kisqali gets FDA approval for early-stage breast cancer; GSK's vaccines for RSV and shingles co-administered effectively; Novo Nordisk partners with NanoVation for genetic therapies; AstraZeneca's Mene Pangalos joins Omega Funds; Serán Biosciences secures $200M for new facility; Boehringer Ingelheim's nerandomilast shows success in Phase 3 IPF trial.
GSK Launches Brooke Shields' Led Campaign Promoting Shingles Vaccine
GSK's Thrive@50 campaign, featuring Brooke Shields, educates people over 50 on shingles risks, promoting vaccination discussions with healthcare providers. GSK also partners with Flagship Pioneering to develop novel treatments for respiratory diseases.
Erythropoietin Drugs Market Estimated to Reach USD 14.3
The global erythropoietin drugs market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $14.3 billion by 2034. Advances in precision medicine, regulatory reforms for biosimilars, and telemedicine integration are driving market growth. Key players include Amgen, Roche, and Johnson & Johnson. Epoetin Alfa and biosimilars lead the market segments.
© Copyright 2025. All Rights Reserved by MedPath